Meiji Seika Kaisha, Ltd.

Meiji Seika Kabushiki Kaisha

Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai

Meiji Saika Kaisha, Ltd.

Meiji Seika Kaburhiki Kaisha

Kiyoaki Katano

Takashi Tsuruoka

Hiroko Ogino

Eiki Shitara

Tomoaki Miura

Tomoya Machinami

Shokichi Ohuchi

Seiji Shibahara

Fukio Konno

Fumiya Hirano

Yasukatsu Yuda

Naoto Ohkura

Tetsuya Matsushima

Yukiko Hiraiwa

Masaharu Shiotani

Shigeki Suzuki

Yuuko Nakatani

Tamako Tomomoto

Motohiro Nishio

Shinichi Kondo

Shigeharu Inouye

Katsuyoshi Iwamatsu

Mitsugu Hachisu

Fumio Kai

Hiroyuki Iida

Masaro Shimizu

Kazue Yaegashi

Midori Ishikawa

Yasuko Isomura

Kenji Asai

Emiko Hatsushiba

Takashi Yoshida

Kunio Atsumi

Masaji Sezaki

Keiichi Ajito

Ken Nishihata

Eiichi Akita

Shigeharu Inoue

Satoru Nakabayashi

Mami Kawaguchi

Takayuki Usui

Dai Kubota

Kazue Sasaki

Shoichi Murakami

Tetsutaro Niizato

Takehiro Yamamoto

Mikio Yamamoto

Shigeharu Inoye

Mieko Nagasawa

Naoki Yamazaki

Minoru Ishikawa

Chidsuko Kuroda

Chizuko Kuroda

Takashi Ando

Takahiro Imai

Shunzo Fukatsu

Yasushi Murai

Tsuneo Okonogi

Shuichi Gomi

Kazuko Kobayashi

Naomi Osada

Hisashi Suzuki

Yasuyuki Ichimaru

Yuji Matsuhashi

Kazumi Ota

Kazue Yasufuku

Kazuyuki Fujishima

Kazumasa Aizawa

Ryoichi Okamoto

Takahiko Satoh

Tomoko Soneda

Naoko Kamitoh

Yamazaki Naoki

Jun Nagura

Hiromi Watanabe

Disclosed are compounds represented by formula (I) which have triglyceride biosynthesis inhibitory activity in the liver and inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein from the liver and particularly have excellent inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein, are free from side effect of accumulation of lipids in the liver, and are useful for the treatment and prevention of hyperlipidemia and arteriosclerotic diseases. In formula (I), Rand Rrepresent alkyl, alkoxy, cycloalkyl, phenyl, alkenyl, alkynyl, or a five- or six-membered saturated or unsaturated heterocyclic ring, or Rand R, together with a nitrogen atom to which Rand Rare attached, may form a ring; Rand Rrepresent a hydrogen atom, alkyl, a halogen atom, hydroxyl, nitrile, alkoxycarbonyl, alkoxy, or carboxyl; or Rand Rmay be attached to each other to form &#x2014;(CH)&#x2014;, &#x2014;N&#x2550;CH&#x2014;, &#x2014;CH&#x2550;N&#x2014;, or &#x2014;(Calkyl)C&#x2550;N&#x2014;; A, D, E, and G each represent a carbon atom, or any one of A, D, E, and G represents a nitrogen atom with the other three each representing a carbon atom; Q represents a nitrogen atom or a carbon atom; Y represents a group represented by formula (II) wherein X represents a hydrogen atom, group &#x2014;C(&#x2550;O)N(R)Ror group &#x2014;C(&#x2550;O)OR, Ris absent or represents a bond, an oxygen atom, a sulfur atom, &#x2014;SO&#x2014;, &#x2014;SO&#x2014;, &#x2014;CH&#x2014;CH&#x2014;, or &#x2014;CH&#x2550;CH&#x2014;, and Rand Rrepresent a hydrogen atom, alkyl, alkoxy, a halogen atom, or hydroxyl; and Z represents &#x2014;(CH)&#x2014;, &#x2014;O&#x2014;(CH)&#x2014;, or &#x2014;C(&#x2550;O)NH&#x2014;(CH)&#x2014;

Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same

Disclosed are compounds represented by formula (I) which have triglyceride biosynthesis inhibitory activity in the liver and inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein from the liver and particularly have excellent inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein, are free from side effect of accumulation of lipids in the liver, and are useful for the treatment and prevention of hyperlipidemia and arteriosclerotic diseases. In formula (I), R and R represent alkyl, alkoxy, cycloalkyl, phenyl, alkenyl, alkynyl, or a five- or six-membered saturated or unsaturated heterocyclic ring, or R and R , together with a nitrogen atom to which R and R are attached, may form a ring; R and R represent a hydrogen atom, alkyl, a halogen atom, hydroxyl, nitrile, alkoxycarbonyl, alkoxy, or carboxyl; or R and R may be attached to each other to form &mdash;(CH ) &mdash;, &mdash;N&boxH;CH&mdash;, &mdash;CH&boxH;N&mdash;, or &mdash;(C alkyl)C&boxH;N&mdash;; A, D, E, and G each represent a carbon atom, or any one of A, D, E, and G represents a nitrogen atom with the other three each representing a carbon atom; Q represents a nitrogen atom or a carbon atom; Y represents a group represented by formula (II) wherein X represents a hydrogen atom, group &mdash;C(&boxH;O)N(R )R or group &mdash;C(&boxH;O)OR , R is absent or represents a bond, an oxygen atom, a sulfur atom, &mdash;SO &mdash;, &mdash;SO&mdash;, &mdash;CH &mdash;CH &mdash;, or &mdash;CH&boxH;CH&mdash;, and R and R represent a hydrogen atom, alkyl, alkoxy, a halogen atom, or hydroxyl; and Z represents &mdash;(CH ) &mdash;, &mdash;O&mdash;(CH ) &mdash;, or &mdash;C(&boxH;O)NH&mdash;(CH ) &mdash;.

Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same

Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same

Nitrogen-containing heterocyclic compounds having antiplatelet aggregation effect and medicinal use thereof

Phenylpiperazine derivatives as integrin &agr;v&bgr;3 antagonists

Aminopiperidine derivates as integrin &agr;v&bgr;3 antagonists

Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same

An objective of the present invention is to provide a compound that has antiarrhythmic activity. The present invention provides a compound of formula (I): ##STR1## wherein R.sup.1 and R.sup.2 each represent H, halogen or lower alkyl which may be substituted by halogen; A represents H, C3-6 cycloalkyl, phenyl which may be substituted by halogen, nitro, or lower alkoxy, a 5-membered or 6-membered heterocyclic ring which may contain N and/or S, --NR.sup.3 R.sup.4 (wherein R.sup.3 and R.sup.4 each represent H or lower alkyl which may be substituted by phenyl), or COR.sup.5 (wherein R.sup.5 represents OH, amino or lower alkoxy); Q represents S or O; m represents 0-18; and n represents 0-2, and pharmaceutically acceptable salts and solvates thereof.

5-(4-piperidinyl)dibenzothiazepine derivatives and

A .gamma.-diketone compound represented by the following formula (I) and a pharmaceutically acceptable salt and solvate thereof having platelet aggregation inhibitory activity is disclosed: ##STR1## wherein B is --Z--(CH.sub.2).sub.q COOR.sup.7 and A is the following group (II) or (III): ##STR2##

.gamma.-diketone compounds with inhibitory activity against platelet

Compounds with platelet aggregation inhibitor activity

.gamma.-Diketone compounds with inhibitory activity against platelet

A compound represented by the general formula (I) and a pharmaceutically acceptable salt and solvate thereof having an effect for inhibiting the agglutination of platelets is disclosed: ##STR1## wherein R.sup.1 represents a group --W--(CH.sub.2).sub.i --COOR.sup.3,

Compound with platelet aggregation inhibitor activity

Pyridine derivatives having angiotensin II antagonism

A novel benzothiazole or benzimidazole derivative represented by formula (I) ##STR1## wherein X represents a sulfur atom or a NH group; R.sup.1 represents a hydrogen atom, a lower alkoxy group, a chlorine atom, a bromine atom or an iodine atom; R.sup.2 represents a hydrogen atom a substituted or unsubstituted lower alkyl group, a vinyl group, an aryl group or an acyl group; m is an integer of 1, 2 or 3; and n is an integer of 0, 1 or 2, which shows an excellent acid secretion suppressing effect and gastric mucosa protecting effect, and an antiulcer agent containing the same as an active ingredient.

Benzothiazole and benzimidazole derivatives and antiulcer agent

Growing community of inventors

Yokohama, Japan

Kiyoaki Katano